Sign up
Log in
Reported Saturday, Johnson & Johnson's TALVEY Plus DARZALEX FASPRO Delivers Up To 81% PFS And 89% OS At 24 Months In First Phase 3 Study To Show Superior PFS For GPRC5D Bispecific Combination In Multiple Myeloma
Share
Listen to the news
  • TALVEY plus DARZALEX FASPRO with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 months
  • MonumenTAL-3 is the third positive study in recent months from Johnson & Johnson's bispecific portfolio and is the first Phase 3 study of a GPRC5D bispecific investigational combination
  • Results reinforce Johnson & Johnson's leadership in multiple myeloma, advancing bispecific combinations earlier in the treatment journey, and expanding options to match the right treatment to the right patient and stage of disease
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
Terms of Service·Privacy Policy·Data Disclaimer
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved